89 FR 48 pg. 17475 - Assessing COVID–19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID–19 Prevention or Treatment; Guidance for Industry; Correction
Type: NOTICEVolume: 89Number: 48Page: 17475
Page: 17475Docket number: [Docket No. FDA–2020–D–1824]
FR document: [FR Doc. 2024–05081 Filed 3–8–24; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2020-D-1824]
Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment; Guidance for Industry; Correction
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Correction.
SUMMARY:
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register on February 22, 2024. The document announced the availability of a final guidance for industry entitled "Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment." The document was published with an incorrect docket number. This document corrects that error.
FOR FURTHER INFORMATION CONTACT:
David Reasner, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, Rm. 6373, Silver Spring, MD 20993, 301-837-7667; or James Myers, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911.
SUPPLEMENTARY INFORMATION:
In the Federal Register of February 22, 2024 (89 FR 13351), in FR Doc. 2024-03622, the following correction is made:
On page 13351, in the first column in the header of the document and in the third column in the second line of the first paragraph, "Docket No. FDA-2024-D-0584" is corrected to read "Docket No. FDA-2020-D-1824."
Dated: March 5, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-05081 Filed 3-8-24; 8:45 am]
BILLING CODE 4164-01-P